Cagrilintide Peptide

Cagrilintide peptide is a novel, long-acting amylin analog, a hormone secreted by pancreatic β-cells in conjunction with insulin. As a non-selective agonist of the amylin receptor (AMYR) and calcitonin G protein-coupled receptor (CTR), it is a cyclic peptide composed of 38 amino acids, featuring a disulfide bond. Cagrilintide significantly reduces body weight and food intake. It holds potential for obesity research.

Xi 'an Tongze can provide other peptide products, the catalog is as follows, welcome to consult!

I. Powerfully and Sustainedly Reduces Hunger and Increases Satiety

This is the core and most direct effect of Cagrilintide whose mechanism directly targets the brain's "appetite control center."

Its mechanism of action includes central targeting, activation of satiety receptors, reshaping of neural signals, and inhibition of "hunger neurons" while activating "satiety neurons."

1. Central targeting: Following injection, Cagrilintide crosses the blood-brain barrier to precisely reach the hypothalamus.

2. Activation of satiety receptors: It binds with high affinity to specific glucagon-like peptide receptors (comprising calcitonin receptor and receptor-activating protein) in the hypothalamus.

3. Neural Signal Remodeling: Upon receptor activation, it triggers potent chemical signaling:

4. Suppression of "Hunger Neurons": It downregulates neuronal activity producing ghrelin and neuropeptide Y, thereby reducing hunger sensations at their source.

5. Activation of "satiety neurons": Such as upregulating pathways like the melanocortin system to enhance and prolong post-meal satisfaction and fullness.

Consequently, individuals subjectively experience sustained satiety and reduced hunger, naturally decreasing food intake per meal.

II: Significant and Sustained Weight Loss

The aforementioned effect of "reducing food intake" directly creates a sustainable caloric deficit, translating into clinical weight loss outcomes.

Through Mechanism I (central appetite suppression), patients experience a substantial, unconscious reduction in daily total caloric intake.

Cagrilintide also acts on the gastrointestinal tract, slowing the passage of gastric contents into the small intestine and thereby delaying gastric emptying. This means the stomach remains physically full for a longer period, sending signals of "stomach fullness" back to the brain via the vagus nerve. This further reinforces the central feeling of satiety and may influence the secretion of gut hormones.

III: Improving Metabolic Complications Associated with Obesity

Significant weight loss itself triggers a series of positive metabolic chain reactions. By achieving Core Benefit II (weight reduction), Cagrilintide indirectly delivers this broad health advantage.

1. The underlying mechanisms are as follows:

Reduced adipose tissue: Particularly the decrease in visceral fat lowers levels of inflammatory cytokines and free fatty acids secreted by adipose tissue.

Enhanced Insulin Sensitivity: Following weight loss, muscles, liver, and adipose tissue become more responsive to insulin, requiring less insulin secretion for effective blood glucose control.

2. Manifestations of Corresponding Effects:

Improved Glycemic Control: In individuals with prediabetes or type 2 diabetes, reductions in fasting and postprandial blood glucose levels, as well as hemoglobin A1c (HbA1c) levels, are observed.

Optimized lipid profile: Typically accompanied by reductions in triglycerides and LDL cholesterol, along with increases in HDL cholesterol.

Lowered blood pressure: Weight loss helps reduce cardiac workload and improve vascular function, thereby decreasing both systolic and diastolic blood pressure.

Reduced waist circumference: Directly reflects improvement in central obesity (visceral fat).

Cagrilintide was developed by Novo Nordisk, the same company that manufactures another well-known weight-loss drug, semaglutide. Its development background is based on the following points:

The global prevalence of obesity: Obesity is a complex chronic disease associated with multiple complications, yet effective and safe long-term treatment options remain limited.

Value of the GLP-1 Pathway: The scientific community has long recognized GLP-1 as a key physiological pathway regulating body weight. However, native GLP-1 is unstable and prone to aggregation, making it unsuitable for direct pharmaceutical use.

Successes and limitations of GLP-1 drugs: GLP-1 receptor agonists like semaglutide have achieved significant success in weight loss, demonstrating the efficacy of hormone-mimetic therapies. However, some patients exhibit poor response or require stronger effects.

Potential of Combination Therapies: Researchers are exploring the combination of drugs with different mechanisms of action to achieve synergistic effects where "1+1>2."

Therefore, the development of Cagrilintide aims to:

Provide a novel, highly effective monotherapy option for weight loss.

Establish a foundation for combination use with GLP-1 drugs (such as Semaglutide) to create more potent weight loss regimens

1.Inquiry methods：
Email:alice@xaheshun.com
Whatspp:+8618509260106

Online instant messaging

2.Contact Information：
Name：Alice

Telephone :+8618509260106
Email:alice@xaheshun.com

Hot Tags: cagrilintide peptide, China cagrilintide peptide manufacturers, suppliers, factory, Fenbendazole for Internal Parasites, Sulforaphane for Anticancer Properties, Loratadine for Allergy Symptom Relief, Fenbendazole for Parasite Treatment in Animals, Dihydroberberine for Weight Loss, Sulforaphane for Liver Health